Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong, P R China.
Guangdong Medical University, Zhanjiang, Guangdong, P R China.
Ann Pharmacother. 2021 May;55(5):624-636. doi: 10.1177/1060028020951954. Epub 2020 Sep 4.
The purpose of this meta-analysis is to assess the effect of dexmedetomidine on delirium in elderly surgical patients.
The Cochrane Library, Web of Science, PubMed, EMBASE, and Google Scholar were searched (January 1, 2000, to February 4, 2020) for randomized controlled trials (RCTs).
RCTs without language restrictions were included if delirium incidence was assessed in elderly surgical patients receiving dexmedetomidine. Intervention and basic information were extracted.
21 studies were included. Dexmedetomidine reduced delirium occurrence (risk ratio [RR] = 0.55; 95% CI = 0.45 to 0.67) in elderly surgical patients with sufficient evidence from trial sequential analysis. Dexmedetomidine did not prevent delirium incidence for cardiac surgery (RR = 0.71; 95% CI = 0.44 to 1.15) with insufficient evidence. Dexmedetomidine decreased mortality incidence (RR = 0.47; 95% CI = 0.25 to 0.89), shortened the length of intensive care unit (ICU; standard mean difference [SMD] = -0.46) and hospital stays (SMD = -0.41), and increased bradycardia incidence (RR = 1.60).
This review revealed that dexmedetomidine could reduce delirium incidence for elderly noncardiac surgical patients, and the effect of dexmedetomidine on delirium for elderly cardiac surgical patients needs further studies to guide clinicians.
Dexmedetomidine reduced delirium incidence in elderly surgical patients. The efficacy of dexmedetomidine on delirium for elderly cardiac surgical patients warrants further studies. Furthermore, dexmedetomidine was associated with an increased bradycardia incidence, shorter length of ICU/hospital stays, and a lower incidence of mortality.
本荟萃分析旨在评估右美托咪定对老年外科手术患者谵妄的影响。
检索 Cochrane 图书馆、Web of Science、PubMed、EMBASE 和 Google Scholar,检索时间为 2000 年 1 月 1 日至 2020 年 2 月 4 日,纳入评估老年外科手术患者接受右美托咪定后谵妄发生率的随机对照试验(RCT)。
纳入无语言限制的 RCT,研究对象为接受右美托咪定治疗的老年外科手术患者,提取干预措施和基本信息。
共纳入 21 项研究。试验序贯分析结果表明,右美托咪定可降低老年外科手术患者谵妄发生率(风险比[RR] = 0.55;95%可信区间[CI] = 0.45 至 0.67),证据充分。但对于心脏手术患者,右美托咪定并不能预防谵妄发生(RR = 0.71;95% CI = 0.44 至 1.15),证据不足。右美托咪定降低死亡率(RR = 0.47;95% CI = 0.25 至 0.89),缩短重症监护病房(ICU)入住时间(标准均数差[SMD] = -0.46)和住院时间(SMD = -0.41),增加心动过缓发生率(RR = 1.60)。
本研究表明,右美托咪定可降低老年非心脏手术患者谵妄发生率,而右美托咪定对老年心脏手术患者谵妄的影响需要进一步研究以指导临床医生。
右美托咪定降低老年外科手术患者谵妄发生率。右美托咪定对老年心脏手术患者谵妄的疗效尚需进一步研究。此外,右美托咪定与心动过缓发生率增加、ICU/住院时间缩短和死亡率降低有关。